Every Cure

Every Cure Receives Five-Year, $60 Million Commitment Through TED's Audacious Project to Repurpose Medications for Global Impact. Full Press Release: https://lnkd.in/eCcwt4Vn TED Conferences The Audacious Project

What makes Every Cure truly unique is our end-to-end approach. We take full responsibility—from the initial hypothesis of whether a drug could work for a disease, to validation through extensive medical review, pre-clinical research, and/or clinical trials, and ultimately, delivery of treatment for patients worldwide. Drug repurposing has historically relied on serendipity—whether through a chance discovery in a lab or a bold, one-off experiment. These insights often remain scattered in the literature, never fully realized as solutions for patients. At Every Cure, we systematically identify these opportunities, unlock their potential, and ensure they don’t just remain ideas on paper. Instead, we see them through to actually saving lives. This is how we’re transforming hope into action and changing the future of medicine. #drugrepurposing #pharma #raredisease #drugdiscovery

The FDA approved a drug for a new disease without requiring a clinical trial! Tacrolimus, initially used off-label for lung transplant rejection, proved so effective that once the data was analyzed, the FDA approved it for this new indication. This highlights the power of real-world evidence analysis, a strategy we embrace at Every Cure. By leveraging patient-level data., we can uncover which drugs are actually working and identify opportunities to expand their use to even more patients. This approach is not only faster and less expensive than traditional clinical trials but also a game-changer in getting lifesaving treatments to people worldwide. #raredisease #pharma #drugdevelopment

So much of our medical system relies on individual ingenuity rather than systematic solutions. Stories like Viagra being repurposed for a rare pediatric lung disease highlight the brilliance of creative doctors, but they also reveal how random and unsystematic drug repurposing can be. At Every Cure, we believe that innovation in medicine shouldn't be left to chance. This randomness can lead to gaps in research and a delayed understanding of a drug's full potential. By establishing more systematic approaches and leveraging advanced algorithms, we can streamline the drug repurposing process, making it more efficient and targeted. As we continue to refine our processes, we aim to transform this landscape, ensuring that creativity in medicine is complemented by a foundation of research and evidence-based practice. This way, patients no longer need to rely on luck or isolated ideas for their health and well-being. What inspires you most about the potential for systematic approaches like this to transform medicine? #raredisease #pharma #drugdevelopment

After years of dreaming and building, we’re thrilled to share the progress we’re making at Every Cure. With our foundational systems and cutting-edge tech platform now in place, we’re diving into the most promising drug-disease matches identified by our algorithm. As we uncover potential drug repurposing opportunities, our dedicated medical team and scientific advisory board will develop customized plans with the greatest potential to transform lives. These plans may include clinical trials, registries, laboratory studies, and/or updates to treatment guidelines, all aimed at maximizing patient access. What’s so exciting is that this vision—more than a decade in the making—is finally coming to life. Thanks to our early supporters, ARPA-H, The Audacious Project, and our incredible team, we’re closer than ever to turning this dream into tangible results for patients who need it most. #HealthcareInnovation #DrugRepurposing #AIForGood #EveryCure #BiomedicalResearch

Congratulations to Every Cure Co-Founder David Fajgenbaum, MD, MBA, MSc on receiving the 2024 Judson Daland Prize in Patient-oriented Clinical Investigation from the American Philosophical Society! This award is in recognition of the work uncovering mechanisms and therapeutics across hyperinflammatory disorders and rare diseases. The prize recognizes outstanding achievement in clinical investigation, particularly patient-oriented research. Learn more about the award: https://lnkd.in/eirZ-KY8

Interesting article by Francois Vanderseypen that dives deep into how TigerGraph and knowledge graphs can identify new uses for existing drugs, offering hope for rare and neglected diseases. At Every Cure, we’re harnessing the power of AI and knowledge graphs, similar to the innovative methods highlighted in this article, to unlock new uses for existing drugs. By analyzing vast amounts of biomedical data, we’re able to identify promising treatment connections that might otherwise go unnoticed. Our approach, using in-depth graph analytics and machine learning, lets us map relationships between drugs, genes, and diseases to reveal potential new treatments for conditions lacking effective therapies. Just like the Drug Repurposing Knowledge Graph (DRKG) helps uncover possibilities for new uses, our platform at Every Cure is dedicated to scanning existing drugs and disease interactions to prioritize the most promising, overlooked treatment options. Read full article: https://lnkd.in/eYn_pt4W #DrugRepurposing #AIforGood #EveryCure #BiomedicalInnovation #UnlockingCures

As we advance in our work, I am excited to share not only Every Cure's progress but also the collective journey we are embarking on together. Please click the link below to read the full letter: https://lnkd.in/evc4X8dZ

It was so great to see Every Cure Co-founder David Fajgenbaum, MD, MBA, MSc on this panel at the Learn Serve Lead 2024: The AAMC Annual Meeting!

Loved being a part of this, Matthew Swift! Thanks for helping to spread the word about my journey #chasingmycure and our work!